Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1478 • ACR Convergence 2024
Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Xenofon Baraliakos¹, Paul Bird², Atul Deodhar³, Dafna Gladman⁴, Philip S. Helliwell⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, Mikkel Ostergaard⁸, Enrique R. Soriano⁹, Lai-shan Tam¹⁰, Soumya Chakravarty¹¹, Evan Leibowitz¹², Cinty Gong¹³, Stephen Xu¹⁴, Thomas Fuerst¹⁵, Nadeem Saeed¹⁶, Robert Landewé¹⁷ and Philip Mease¹⁸, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California San Diego, La Jolla, CA, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰The Chinese University of Hong Kong, New Territories, Hong Kong, ¹¹Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ¹²Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ¹³Janssen Scientific Affairs, Horsham, PA, ¹⁴Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁵Clario, San Mateo, CA, ¹⁶Clario, San Mateo, ¹⁷Amsterdam University Medical Center, Meerssen, Netherlands, ¹⁸Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…
Abstract Number: 2050 • ACR Convergence 2024
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
caroline pignon¹, Laure Gossec², Bruno Fautrel³, Clementina López Medina⁴ and Noemie bibas⁵, ¹Faculté de médecine Créteil, PARIS, France, ²Sorbonne Université, Paris, France, ³INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁴Reina Sofia University Hospital, Cordoba, Spain, ⁵Sorbonne Université, paris
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
Abstract Number: 2323 • ACR Convergence 2024
The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis
Keith Colaco¹, laura bumbulis², Vinod Chandran¹, Richard Cook³, Dafna Gladman⁴ and Lihi Eder⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³University of Waterloo, Waterloo, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…
Abstract Number: 2340 • ACR Convergence 2024
Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Jessica A Walsh¹, Shaobo Pei², Gopi Penmetsa³, Swetha Alexander⁴, Nga Lori Ly⁵, Rosario Adriana Molano-Romero⁴, April Conlon⁶, Catherine Bakewell⁷, Soumya Reddy⁸, Jose Scher⁹ and Alexis Ogdie¹⁰, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²University of Utah, Thousand Oaks, CA, ³University Of Utah Hospital, Salt Lake City, UT, ⁴University of Utah Health, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah, Sandy, UT, ⁷Intermountain Healthcare, Salt Lake City, UT, ⁸NYU Grossman School of Medicine, New York, NY, ⁹New York University School of Medicine, New York, NY, ¹⁰Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
Abstract Number: 2367 • ACR Convergence 2024
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Philip Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Alexander Marten⁴, Ute Massow⁴, Vishvesh Shende³, Myriam Manente⁵, Luke Peterson⁶, Katy White³, Peter Nash⁷ and Lianne S Gensler⁸, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Charite-Universitatsmedizin Berlin, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim am Rhein, Germany, ⁵UCB Pharma, Braine-l'Alleud, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
Abstract Number: 0187 • ACR Convergence 2024
Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
Abstract Number: 0550 • ACR Convergence 2024
Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study
Nelly Ziade¹, Ihsane Hmamouchi², Clementina López Medina³, Maroun Aoun⁴, Sherif Gamal⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²International University of Rabat, Rabat, Morocco, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Saint Joseph University, Beirut, Lebanon, ⁵Cairo University, Cairo, Egypt, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
Abstract Number: 0600 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Laure Gossec¹, Dafna Gladman², Laura Coates³, Maarten de Wit⁴, Barbara Ink⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Jérémy Lambert⁷ and Ana-Maria Orbai⁸, ¹Sorbonne Université, Paris, France, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁴Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Colombes, France, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…
Abstract Number: 1128 • ACR Convergence 2024
A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis
Barbara Abreu Lopez¹, Ernesto Calderon Martinez², Tania Siu Xiao³, Zulma Sosa Carcamo⁴, Alejandra Maria Aleman Reyes⁵, Felix Ricardo Bonilla Bonilla⁶, María Isabel Murillo Pineda⁵, Edgar Josué Sanabria Herrera⁷, Alberto Ayala Aguilar⁸, Adreina Del Valle Rojas Marron⁹, Valentina Contreras Duran,¹⁰, Kevin J. Lopez Romero¹¹ and Marcela Garzon¹², ¹Universidad de Carabobo, Carabobo, Venezuela, ²The University of Texas Science Medical Center at Houston, Tomball, ³Thomas Jefferson University Hospital, Philadelphia, ⁴Universidad Evangélica de El Salvador, San Salvador, El Salvador, ⁵Universidad Católica de Honduras, Tegucigalpa, Honduras, ⁶Hospital Militar Central, San Salvador, El Salvador, ⁷Universidad Nacional Autónoma de Honduras, Tegucigalpa, ⁸Baylor College of Medicine, Houston, ⁹Universidad de Oriente Núcleo Anzoátegui, Barcelona, Venezuela, ¹⁰MD Anderson Cancer Center, Texas, Houston, ¹¹Universidad de El Salvador, San Salvador, El Salvador, ¹²Universidad de Los Andes, Bogotá, Colombia
Background/Purpose: Psoriasis is a chronic inflammatory skin disorder that is associated with an increased risk of cardiovascular diseases. Chronic inflammation in psoriasis can produce excessive…
Abstract Number: 1456 • ACR Convergence 2024
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Lija James¹, Elnaz Saeedi², Jean-Guillaume Letarouilly¹, Nicola Gullick³, Anne Francis², Deepak Jadon⁴, William Tillett⁵, Yvonne Sinomati², Laura Tucker¹, Nadia Mian², Ines Rombach², Ioana Marian², Maria Sofia Massa² and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁴Cambridge University, Cambridge, United Kingdom, ⁵Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁶University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic musculoskeletal disease, which can lead to progressive joint pain, joint destruction, and loss of function. Evidence suggests that…
Abstract Number: 1479 • ACR Convergence 2024
Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
Philipp Sewerin¹, Nicola Gullick², Hagen Russ³, Khai Jing Ng⁴, meadhbh O’Neill⁵, Sebastián Moyano⁶, Federica Giurdanella⁵, Adela Gallego- Flores⁷ and Francesco Ciccia⁸, ¹Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ²University Hospitals Coventry & Warwickshire NHS trust, Warwickshire, United Kingdom, ³Eli Lilly, Indianopolis, ⁴Eli Lilly and Company, Madrid, Spain, ⁵Eli Lilly, Indianopolis, IN, ⁶Eli Lilly and Company, Alcobendas, Spain, ⁷Hospital Perpetuo Socorro, Badajoz, Spain, ⁸Università degli studi della Campania Luigi Vanvitelli, Naples, Italy
Background/Purpose: Treatment (tx) guidelines for PsA recommend biologic DMARDs (bDMARDs) or targeted synthetic (ts) DMARDs after inadequate response to conventional synthetic DMARDs (csDMARDs)1. In clinical…
Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…
Abstract Number: 2324 • ACR Convergence 2024
Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients with and Without First-degree Relatives with Psoriatic Disease
Catherine Howe¹, Weixi Chen², Jiyuan Hu², Kyra Chen³, Adamary Felipe³, Stephanie Eichman³, Margaret Coyle⁴, Eileen Lydon⁵, Andrea Neimann³, Soumya Reddy⁶, Jose Scher⁷ and Rebecca haberman⁸, ¹New York University Langone Medical Center, New York, NY, ²Division of Biostatistics, Department of Population Health, New York, NY, ³NYU Grossman School of Medicine, NYC, ⁴NYU Langone, Brooklyn, NY, ⁵NYU, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷New York University School of Medicine, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease of the joints, affecting up to a third of individuals with cutaneous psoriasis. Pathogenesis remains…
Abstract Number: 2341 • ACR Convergence 2024
Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
Lihi Eder¹, Elena Muensterman², Desiree van der Heijde³, Alan Kivitz⁴, Mona Trivedi⁵, Ting Hong⁵, Muhammad Rehman⁵, Haoling Weng⁶, Jingjing Chen⁵ and Xenofon Baraliakos⁷, ¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ²Takeda Development Center Americas, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶HW MedAdvice LLC, San Diego, CA, ⁷Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is a potent, highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor. In a recent phase 2b trial in active psoriatic arthritis…
Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Philip Mease¹, William Tillett², Maarten de Wit³, Laure Gossec⁴, M. Elaine Husni⁵, Fabian Proft⁶, Barbara Ink⁷, Rajan Bajracharya⁷, Jason Coarse⁸, Jérémy Lambert⁹, Laura Coates¹⁰ and Alice Gottlieb¹¹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁴Sorbonne Université, Paris, France, ⁵Cleveland Clinic, Cleveland, OH, ⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Colombes, France, ¹⁰University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…

« Previous Page
1
…
5
6
7
8
9
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].